Use of intraputaminal infused glial cellline derived neurotrophic factor in the treatment of Parkinson's disease in humans

Details for Australian Patent Application No. 2004216251 (hide)

International Classifications

Event Publications

8 September 2005 PCT application entered the National Phase

PCT publication WO2004/075720 Priority application(s): WO2004/075720

6 April 2006 Assignment before Grant

University of Kentucky; North Bristol N.H.S. Trust The application has been assigned to Amgen, Inc.; University of Kentucky

10 June 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.